MiNK Therapeutics (INKT) vs Instil Bio (TIL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MiNK Therapeutics (INKT) has outperformed Instil Bio (TIL) over the past year, losing 24.1% versus a loss of 60.2%. Over five years, INKT leads with a -96.0% price change compared with -98.7% for TIL. MiNK Therapeutics is the larger company by market cap ($41.2 million vs $35.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INKT | TIL |
|---|---|---|
| Share price | $8.02 | $5.23 |
| Market cap | $41.17M | $35.47M |
| 1-day change | -6.85% | -5.77% |
| YTD return | -28.07% | -52.45% |
| 1-year return | -24.05% | -60.20% |
| 5-year return | -95.99% | -98.72% |
| EPS (TTM) | $-2.23 | $-3.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $10.77M |
| Revenue growth (YoY) | — | +152.38% |
| Net income (latest FY) | $-12.49M | $-71.37M |
| Operating margin | — | -745.39% |
| Net margin | — | -662.75% |
| 52-week high | $16.93 | $12.92 |
| 52-week low | $7.76 | $5.14 |
| Distance from 52-week high | -52.62% | -59.51% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +386.28% | +33.84% |
| Average volume | 15.74K | 42.02K |
| Shares outstanding | 5.13M | 6.78M |
| Employees | 15 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INKT has outperformed TIL by 36.1 percentage points over the past year.
About MiNK Therapeutics
INKT stock →MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
About Instil Bio
TIL stock →Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
INKT vs TIL FAQ
Which is bigger, MiNK Therapeutics or Instil Bio?
MiNK Therapeutics (INKT) is larger, with a market capitalization of $41.17M compared with $35.47M for Instil Bio (TIL).
Which stock has performed better over the past year, INKT or TIL?
INKT returned -24.05% over the past 12 months, compared with -60.20% for TIL (price return, excluding dividends). Past performance does not predict future results.
Are MiNK Therapeutics and Instil Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.